Caribou Biosciences, Inc. announced the appointments of Dara Richardson-Heron, M.D., to its board of directors and Ruhi Khan as its chief business officer. Dr. Richardson-Heron has more than 25 years of leadership experience in the healthcare, corporate, nonprofit, and government sectors. Ms. Khan brings over 20 years of business development and investment management experience focused on the biotechnology and pharmaceutical industries. Dr. Richardson-Heron most recently served as Pfizer?s chief patient officer. Prior to joining Pfizer, Dr. Richardson-Heron served as the chief engagement officer and scientific executive for the National Institutes of Health?s (NIH) All of Us Research Program. Ms. Khan most recently was the founder of an advisory firm that provided business development and finance advice to life science companies. Previously, she served as head and vice president of business development for Acorda Therapeutics, Inc. Prior to Acorda, she worked in a similar capacity at Lexicon Pharmaceuticals, Inc.